In the Claims:

The current status of all claims is listed below and supercedes all previous lists of claims.

Please cancel claims 10 and 12, amend claims 3-7, 11, 13-18, 22-26, 28, and 30 as follows:

1. (original) A vaccine composition comprising isolated inverted microsomes from an animal cell, or membrane fragments thereof, in association with an externally disposed peptide antigen and a protein of the Major Histocompatibility Complex (MHC).

2. (original) A composition as claimed in claim 1, in which the microsome is from the endoplasmic reticulum of the cell.

3. (currently amended) A composition as claimed in claim 1 ~~or claim 2~~, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.

4. (currently amended) A composition as claimed in ~~any preceding claim~~ claim 1, in which the composition additionally comprises one or more co-stimulatory molecules.

5. (currently amended) A composition as claimed in claim 4, in which the co-stimulatory molecules are selected from ~~the group consisting of~~ B7 and ~~IL-2~~ IL-2.

6. (currently amended) A composition as claimed in ~~any preceding claim~~ claim 1, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan origin.

7. (currently amended) A composition as claimed in ~~any preceding claim~~ claim 1, in which the antigen is an ~~auto-antigen~~ auto-antigen.

8. (original) A composition as claimed in claim 6, in which the antigen is of neoplastic cell or cell of a cancer tumour, or a normal self-protein.

9. (original) A composition as claimed in claim 8, in which the neoplastic cell or cancer cell tumour is from a melanoma, lung adenocarcinoma, colon cancer, breast cancer or leukemia cell.

10. (cancelled).

11. (currently amended) A method of treatment or prophylaxis of a subject suffering from a disease or condition, comprising ~~the step of~~ administering to the subject a vaccine as ~~defined in any one of claims 1 to 9~~ claimed in claim 1 to treat said disease or condition.

12. (cancelled).

13. (currently amended) ~~A use as claimed in claim 12~~ A method as claimed in claim 11, in which the disease is an infection caused by a virus, bacterium, yeast, fungus or protozoan.

14. (currently amended) ~~A use as claimed in claim 12~~ A method as claimed in claim 11, in which the disease is cancer.

15. (currently amended) A ~~use~~ method as claimed in claim 14, in which the cancer is melanoma, lung adenocarcinoma, colon cancer, breast cancer, or leukemia.

16. (currently amended) ~~A use as claimed in claim 12~~ A method as claimed in claim 11, in which the disease is an autoimmune condition.

17. (currently amended) A use method as claimed in claim 16, in which the autoimmune condition is Multiple Sclerosis, Rheumatoid arthritis or Systemic Lupus Eryhamatosus.

18. (currently amended) A process for the preparation of a vaccine composition as ~~defined in any one of claims 1 to 9, the process~~ claimed in claim 1 comprising incubating a population of microsomes and an antigen in the presence of a nucleoside triphosphate, followed by processing to prepare inverted microsomes and formulating the resulting preparation in an physiological diluent and optionally an adjuvant.

19. (original) A process as claimed in claim 18, in which the microsome is from the endoplasmic reticulum of the cell.

20. (original) A process as claimed in claim 18, in which the protein of the MHC is from a heterologous source with respect to the cell from which the microsomes are obtained.

21. (original) A process as claimed in claim 18, in which the protein of the MHC is from an autologous source with respect to the cell from which the microsomes are obtained.

22. (currently amended) A process as claimed in ~~any one of claims 18 to 21~~ claim 18, in which the composition additionally comprises one or more co-stimulatory molecules.

23. (currently amended) A process as claimed in claim 22, in which the co-stimulatory molecules are selected from ~~the group consisting of~~ B7 and IL-2

24. (currently amended) A process as claimed in ~~any one of claims 18 to 23~~ claim 18, in which the antigen is from a viral, bacterial, yeast, fungal, or protozoan antigen.

25. (currently amended) A process as claimed in ~~any one of claims 18 to 23~~ claim 18, in which the antigen is an ~~auto-antigen~~ auto-antigen.

26. (currently amended) A process as claimed in ~~any one of claims 18 to 23~~ claim 18, in which the antigen is of neoplastic cell or cell of a cancer tumour, or a normal self-protein.

27. (original) A process as claimed in claim 26, in which the neoplastic cell or cancer cell tumour is from a melanoma, lung adenocarcinoma, colon cancer, breast cancer or leukemia cell.

28. (currently amended) A kit of parts comprising a composition as ~~defined in any one of claims 1 to 9~~ claimed in claim 1 and one or more cytokines and/or adjuvants in sealed containers.

29. (original) A kit of parts as claimed in claim 28, in which the cytokine is Il-2 or IFNγ

30. (currently amended) A kit of parts comprising a composition as ~~defined in any one of claims 1 to 9~~ claimed in claim 1 and one or more cytokines and/or adjuvants for separate, subsequent or simultaneous administration to a subject.

31. (original) A kit of parts as claimed in claim 30, in which the cytokine is Il-2 or IFNγ